GM-CSF
Showing 1 - 25 of 2,816
Objective Response Rate Trial in Wuhan (GM-CSF)
Recruiting
- Objective Response Rate
- GM-CSF
-
Wuhan, Hubei, ChinaRenmin Hospital of Wuhan University
Feb 25, 2023
Renal Cancer Trial in Boston (Dendritic Cell Tumor Fusion Vaccine, Granulocyte Macrophage Colony Stimulating Factor (GM-CSF))
Active, not recruiting
- Renal Cancer
- Dendritic Cell Tumor Fusion Vaccine
- Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
-
Boston, MassachusettsBeth Israel Deaconess Medical Center
Jan 2, 2023
Neuroblastoma Trial in New York (dietary supplement, drug, biological)
Recruiting
- Neuroblastoma
- β-glucan
- +2 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Dec 5, 2022
Platinum Sensitive Ovarian Cancer, Ovarian Cancer Trial in United States (FRa peptide plus Adjuvant (GM-CSF), Adjuvant (GM-CSF)
Terminated
- Platinum Sensitive Ovarian Cancer
- Ovarian Cancer
- FRα peptide plus Adjuvant (GM-CSF)
- Adjuvant (GM-CSF) Alone
-
Birmingham, Alabama
- +17 more
Nov 21, 2022
Transplant-Related Hematologic Malignancy Trial in Atlanta (Sargramostim, Control Arm)
Recruiting
- Transplant-Related Hematologic Malignancy
- Sargramostim
- Control Arm
-
Atlanta, GeorgiaNorthside Hospital
Oct 19, 2022
Neuroblastoma Trial in New York (Hu3F8, GM-CSF, Isotretinoin)
Active, not recruiting
- Neuroblastoma
- Hu3F8
- +2 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Jul 1, 2022
NSCLC, Carcinoma Breast Trial in Suzhou (Vinorelbine, Radiotherapy, PD-1/PD-L1 inhibitor)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- Carcinoma Breast
- Vinorelbine
- +4 more
-
Suzhou, ChinaSecond Affiliated Hospital of Soochow University
Oct 29, 2022
Recurrent Osteosarcoma Trial in Los Angeles, New York, Houston (humanized anti-GD2 antibody, GM-CSF)
Recruiting
- Recurrent Osteosarcoma
- humanized anti-GD2 antibody
- GM-CSF
-
Los Angeles, California
- +2 more
Dec 22, 2022
Unresectable Melanoma, Metastatic Melanoma, Stage III Melanoma Trial in Boston (Sargramostim (GM-CSF), Pembrolizumab
Recruiting
- Unresectable Melanoma
- +3 more
- Sargramostim (GM-CSF)
- Pembrolizumab (anti-PD-1)
-
Boston, Massachusetts
- +1 more
Jul 6, 2022
Neuroblastoma Trial in New York (Hu3F8 With GM-CSF)
Active, not recruiting
- Neuroblastoma
- Hu3F8 With GM-CSF
-
New York, New YorkMemorial Sloan Kettering Cancer Center
May 2, 2022
Colorectal Tumors Trial in Xiamen (hypofractionation Radiotherapy, sintilimab, GM-CSF)
Recruiting
- Colorectal Neoplasms
- hypofractionation Radiotherapy
- +3 more
-
Xiamen, Fujian, ChinaThe First Affiliated Hospital of Xiamen University
Mar 28, 2022
Down Syndrome Trial in Aurora (Sargramostim for Injection, Saline Placebo)
Not yet recruiting
- Down Syndrome
- Sargramostim for Injection
- Saline Placebo
-
Aurora, ColoradoUniversity of Colorado Anschutz Medical Campus
Jul 28, 2022
Glioma, Malignant Trial in Bangkok (ERC1671, GM-CSF, Cyclophosphamide)
Not yet recruiting
- Glioma, Malignant
- ERC1671
- +3 more
-
Bangkok, Vadhana, ThailandBumrungrad International Hospital
May 9, 2022
Ependymoma, Recurrent Childhood, Ependymoma Trial in Denver, Orlando (Granulocyte Macrophage Colony Stimulation Factor)
Active, not recruiting
- Ependymoma, Recurrent Childhood
- Ependymoma
- Granulocyte Macrophage Colony Stimulation Factor
-
Denver, Colorado
- +1 more
Feb 8, 2022
Neuroblastoma Recurrent Trial in Worldwide (Naxitamab and GM-CSF in combination with irinotecan and temozolomide)
Terminated
- Neuroblastoma Recurrent
- Naxitamab and GM-CSF in combination with irinotecan and temozolomide
-
Hong Kong, Hong Kong
- +2 more
Nov 8, 2022
Neuroblastoma Trial in Guangzhou (Naxitamab monotherapy, GM-CSF, Irinotecan)
Recruiting
- Neuroblastoma
- Naxitamab monotherapy
- +6 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Aug 31, 2023
Carcinoma, Solid Tumor Trial in Suzhou (ADC Combined With Radiotherapy, PD-L1 Sequential GM-CSF and Thymopentin)
Not yet recruiting
- Carcinoma
- Solid Tumor
- ADC Combined With Radiotherapy, PD-L1 Sequential GM-CSF and Thymopentin
-
Suzhou, ChinaSecond Affiliated Hospital of Soochow University
Oct 26, 2023
Biliary Cancer Trial in San Francisco (Pembrolizumab, Sargramostim)
Completed
- Biliary Cancer
-
San Francisco, CaliforniaUniversity of California San Francisco
Jan 21, 2022
Posterior Fossa Ependymoma (PFEPN) Trial in Aurora (Trastuzumab after SubQ GM-CSF, Trastuzumab in combination with SubQ GM-CSF)
Recruiting
- Posterior Fossa Ependymoma (PFEPN)
- Trastuzumab after SubQ GM-CSF
- Trastuzumab in combination with SubQ GM-CSF
-
Aurora, ColoradoChildren's Hospital Colorado
Dec 2, 2021
Alzheimer Trial in Aurora (Sargramostim, Saline - comparator)
Recruiting
- Alzheimer Disease
- Sargramostim
- Saline - placebo comparator
-
Aurora, ColoradoUniversity of Colorado Anschutz Medical Campus
Jul 19, 2022
Glioblastoma Trial in Durham (Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF, Temozolomide, Tetanus-Diphtheria
Suspended
- Glioblastoma
- Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF
- +4 more
-
Durham, North CarolinaDuke University Medical Center
Aug 16, 2022
Multiple Myeloma Trial in Baltimore (biological, drug, other)
Recruiting
- Multiple Myeloma
- GM-CSF vaccine
- +4 more
-
Baltimore, MarylandSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Jan 6, 2022
Hepatitis B, Chronic Trial in Beijing (Granulocyte Macrophage-colony Stimulating Factor, Entecavir)
Terminated
- Hepatitis B, Chronic
- Granulocyte Macrophage-colony Stimulating Factor
- Entecavir
-
Beijing, Beijing, China302 Military Hospital
Mar 9, 2022
Metastatic Melanoma Trial in Louisville (Ipilimumab, GM-CSF)
Completed
- Metastatic Melanoma
- Ipilimumab
- GM-CSF
-
Louisville, KentuckyJames Graham Brown Cancer Center
Oct 22, 2021